These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25259653)

  • 1. Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects.
    Guo J; Zhou D; Grimm SW; Bui KH
    Xenobiotica; 2015 Mar; 45(3):244-55. PubMed ID: 25259653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder.
    Agbo F; Bui KH; Zhou D
    J Clin Pharm Ther; 2017 Oct; 42(5):539-546. PubMed ID: 28474366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects.
    Bui KH; Zhou D; Agbo F; Guo J
    J Clin Pharmacol; 2015 Sep; 55(9):1024-30. PubMed ID: 25880724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
    Karanam B; Addy C; Bateman T; Reddy VB; Li S; Dean D; Li H; Jones A; Schenk D; Zhang AS; Braun M; Freeman A; Flach S; Stoch A; Chodakewitz J; Wagner JA; Kumar S
    Xenobiotica; 2010 Oct; 40(10):691-700. PubMed ID: 20722472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
    Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
    Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
    Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
    Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
    Johnson KA; Prakash C
    Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
    Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
    Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
    Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
    Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
    Tiseo PJ; Perdomo CA; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C; Cui D; Potchoiba MJ; Butler T
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.
    Walles M; Wolf T; Jin Y; Ritzau M; Leuthold LA; Krauser J; Gschwind HP; Carcache D; Kittelmann M; Ocwieja M; Ufer M; Woessner R; Chakraborty A; Swart P
    Drug Metab Dispos; 2013 Sep; 41(9):1626-41. PubMed ID: 23775850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.